Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced the launch of AgentSCREEN ...

From Days to Hours: MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader in molecular diagnostics, announces the integration of ...

Implementation and assessment of a provincial early palliative care initiative for patients with pancreatic cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...

Under the terms of the agreement, Quest will offer ctDx FIRST to healthcare providers in the United States seeking a minimally invasive liquid biopsy test option as a CDx for KRAZATI. Healthcare ...

Ciombor estimated that 1 in 5 patients has metastatic disease at the time of diagnosis. Some 50% of patients with stage III disease who receive surgery alone eventually have a recurrence; the addition ...

Precision medicine is shifting focus to target-based approaches, requiring timely diagnostic testing, yet access remains uneven across different settings. Community oncology practices are leveraging ...

(MENAFN- GlobeNewsWire - Nasdaq) The global rapid microbiology testing market is experiencing significant growth, driven by the need for faster infection diagnosis and pharmaceutical quality control.

Market Outlook and Growth TrajectoryThe global next generation sequencing market is poised to experience robust expansion, registering an estimated growth rate of around 15% over the next five years.

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.